Antiangiogenic properties of 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin: An orally bioavailable heat shock protein 90 modulator

Clinical Cancer Research

Volumn 10, Issue 14, 2004, Pages 4813-4821

  Kaur, Gurmeet ^a   Belotti, Dorina ^b   Burger, Angelika M ^c   Fisher Nielson, Kirsten ^d   Borsotti, Patrizia ^b   Riccardi, Elena ^b   Thillainathan, Jagada ^d   Hollingshead, Melinda ^a   Sausville, Edward A ^a   Giavazzi, Raffaella ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DEMETHOXYGELDANAMYCIN; 17 DIMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANGIOGENESIS INHIBITOR; ANSAMYCIN DERIVATIVE; CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MATRIGEL; NSC 707545; PROTEIN KINASE B; RAF PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; APOPTOSIS; BENZOQUINONES; BIOLOGICAL AVAILABILITY; BLOOD VESSELS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIAL CELLS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LACTAMS, MACROCYCLIC; LAMININ; MICE; MICE, INBRED C57BL; PROTEOGLYCANS; QUINONES; RIFABUTIN; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3242670482     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0795     Document Type: Article

References (34)

1. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7.
2. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239-50.
3. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti- cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17:361-73.
4. Hartmann F, Horak EM, Cho C, et al. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines. Int J Cancer 1997;70:221-9.
5. Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1- Ras association. J Biol Chem 1995;270:24585-8.
6. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994;91:8324-8.
7. Blagosklonny MV, Toretsky J, Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 1995;11:933-9.
8. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10.
9. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002;277:29936-44.
10. Minet E, Mottet D, Michel G, et al. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 1999;460:251-6.
11. Dias S, Shmelkov SV, Lam G, Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002;99:2532-40.
12. Rousseau S, Houle F, Kotanides H, et al. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 2000;275:10661-72.
13. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, Sessa WC. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 1998;392:821-4.
14. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001;89:866-73.
15. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001;7:345-50.
16. Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-82.
17. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003;3:377-83.
18. Giavazzi R, Nicoletti MI. Small molecules in anti-angiogenic therapy. Curr Opin Investig Drugs 2002;3:482-91.
19. Egorin MJ, Lagattuta TF, Hamburger DR, et al. Pharmacokinetics, tissue distribution, and metabolism of 17- (dimethylaminoethylamino)-17- demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 2002;49:7-19.
20. Egorin MJ, Rosen DM, Wolff JH, Gallery PS, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998;58:2385-96.
21. Borgel SD, Carter JP, Sausville E, Hollingshead M. The impact of tumor location on the activity of 17-DMAG (NSC707545), a water soluble geldanamycin analog. Proc. AACR-NCI-EORTC Internatl Conference-Mol Targets Cancer Ther 2003;196.
22. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 2001;7:2076-84.
23. Passaniti A, Taylor RM, Pili R, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Investig 1992;67:519-28.
24. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
25. Vanzulli S, Gazzaniga S, Braidot MF, et al. Detection of endothelial cells by MEC 13.3 monoclonal antibody in mice mammary tumors. Biocell 1997;21:39-46.
26. Vecchi A, Garlanda C, Lampugnani MG, et al. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol 1994;63:247-54.
27. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 2001;47:291-302.
28. Burger AM, Fiebig HH, Stinson SF, Sausville E. 17-(allylamino)-17- demethoxy-geldanamycin activity in human melanoma models., Anticancer Drugs; in press; 2004.
29. Webb CP, Hose CD, Koochekpour S, et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-meturokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000;60:342-9.
30. de Candia P, Solit DB, Giri D, et al. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci USA 2003;100:12337-42.
31. Dowlati A, Haaga J, Remick SC, et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 2001;7:2971-6.
32. Schirner M, Hoffmann J, Menrad A, Schneider MR. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 1998;4:1331-6.
33. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Investig 2000;105:R15-24.
34. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.